New Trends in Therapy: From Natural Products to Nanomedicine, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2857

Special Issue Editors


E-Mail Website
Guest Editor
Institute of Nutrition and Food Technology “José Mataix Verdú”, Department of Physiology, Biomedical Research Center, University of Granada, Avda del Conocimiento sn., 18100 Armilla, Granada, Spain
Interests: metals; nanoparticles; micronutrients
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Biomedical Research Centre, Institute of Nutrition and Food Technology, Department of Physiology, Faculty of Pharmacy, University of Granada, 18016 Granada, Spain
Interests: nanomedicine; food technology; nutrition
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biomedical sciences are now focused on developing secure and personalized medicine using new methods for disease treatment. This progress will be achieved through interdisciplinary research collaboration.

The search for new therapeutic tools is being advanced by a variety of disciplines, including from natural products as medicinal plants, as a source of biochemical compounds, to the use of nanoplatform as a carrier of drug delivery. The aim of this Special Issue is to contribute new alternatives of drug discovery and clarify the mechanisms of action.

Prof. Dr. Juan Llopis
Prof. Dr. Cristina Sánchez González
Dr. Lorenzo Rivas García
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • nutrition
  • natural products
  • cancer
  • polyphenols
  • food industry
  • drug delivery

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 2650 KiB  
Review
TACkling Cancer by Targeting Selective Protein Degradation
by María del Mar Noblejas-López, David Tébar-García, Raquel López-Rosa, Ana Alcaraz-Sanabria, Pablo Cristóbal-Cueto, Alejandro Pinedo-Serrano, Lorenzo Rivas-García and Eva M. Galán-Moya
Pharmaceutics 2023, 15(10), 2442; https://doi.org/10.3390/pharmaceutics15102442 - 10 Oct 2023
Cited by 2 | Viewed by 2417
Abstract
Targeted protein degradation has emerged as an alternative therapy against cancer, offering several advantages over traditional inhibitors. The new degrader drugs provide different therapeutic strategies: they could cross the phospholipid bilayer membrane by the addition of specific moieties to extracellular proteins. On the [...] Read more.
Targeted protein degradation has emerged as an alternative therapy against cancer, offering several advantages over traditional inhibitors. The new degrader drugs provide different therapeutic strategies: they could cross the phospholipid bilayer membrane by the addition of specific moieties to extracellular proteins. On the other hand, they could efficiently improve the degradation process by the generation of a ternary complex structure of an E3 ligase. Herein, we review the current trends in the use of TAC-based technologies (TACnologies), such as PROteolysis TArgeting Chimeras (PROTAC), PHOtochemically TArgeting Chimeras (PHOTAC), CLIck-formed Proteolysis TArgeting Chimeras (CLIPTAC), AUtophagy TArgeting Chimeras (AUTAC), AuTophagosome TEthering Compounds (ATTEC), LYsosome-TArgeting Chimeras (LYTAC), and DeUBiquitinase TArgeting Chimeras (DUBTAC), in experimental development and their progress towards clinical applications. Full article
Show Figures

Figure 1

Back to TopTop